AAAAI 2020 has been cancelled due to COVID19. It would have been the second time SCIREQ would participate and in the wake of the recent 2019-nCoV outbreak, we wanted to highlight how our preclincial respiratory equipment can help researchers advance our understanding of Infectious Respiratory Diseases.
Coronaviruses are a family of viruses that can cause severe respiratory illnesses and infections, leading to impaired lung function and respiratory failure manifestations such as Acute Respiratory Distress Syndrome (ARDS). Current treatment includes antibiotics, corticosteroids and oxygen support via mechanical ventilation, but no effective vaccines have been developed. Further preclinical studies are required to investigate the pathophysiology of these diseases, which remains poorly understood.
The flexiVent can help researchers advance our understanding surrounding the mechanisms of host response and pathogenesis of viruses. These insights will allow for fast countermeasure developments, preventing the rapid spread of viruses such as the 2019-nCoV.
The inExpose administers drugs and novel therapeutic carriers through the inhalation pathway, a preferential route for preclinical models. It standardizes experimental conditions providing reproducible, practical and relevant animal models.
The vivoFlow whole-body plethysmograph tracks changes in ventilatory parameters throughout the progression of respiratory infection. This technique provides continuous respiratory recordings including measures of respiratory rate, estimated tidal volumes and minute ventilation.
SCIREQ Scientific Respiratory Equipment Inc.
Head Office : 6600 St-Urbain Suite 300 Montreal, QC H2S 3G8 Canada
Telephone: Toll free 1 (877) 572-4737 or 1 (514) 286-1429
info@scireq.com